Navigation Links
UC San Diego Offers New Certificate for Clinical Trials Administration in Latin America
Date:11/9/2010

LA JOLLA, Calif., Nov. 9, 2010 /PRNewswire/ -- The clinical trials program at UC San Diego Extension, one of the first and most widely recognized educational programs of its kind in the world, is now accepting international students for its new Clinical Trials Administration in Latin America Certificate.

Classes are taught by Spanish-speaking medical faculty with practical, international experience. Medica Sur, one of the most respected physician/research groups in Mexico, is sending the first cohort of students through the program.

"The demand for clinical trials in Latin America is expected to grow tenfold in the next five years," says Dr. Leonel Villa-Caballero, the director of the Latin America clinical trials program. "Our certificate helps clinicians and other health professionals meet this demand for specific expertise in the design and administration of trials that will meet high government standards in the region. We are happy to offer a high-quality program for the growing audience and pharmaceutical industry in need of clinical trial education in Latin America."

Three sections are needed to complete the Clinical Trials Administration in Latin America Certificate. Phase one can be taken online or in-person, which provides networking opportunities with UC San Diego faculty and San Diego industry leaders. Phase two and three are taught fully online. The certificate can be completed in as little as six months.

Pharmaceutical and medical device development has become one of the premier industries of the 21st Century, with Latin America taking an international role in biomedical research and biotechnical development. Critical to the industry are clinical trials, the experiments to evaluate new drugs, medical devices or other interventions on patients in strictly scientifically controlled settings that are required for regulatory authority approval of new therapies.

"Offering a clinical trials program totally in Spanish ensures we are reaching the important Latin America research market in addition to researchers and clinicians in Spain," says Dr. Villa-Caballero.

Today's clinical trials require careful planning and cooperation among a variety of professionals within the pharmaceutical and biotechnical industry, clinical practice, and governmental or industrial agencies who need both specialized expertise and general familiarity with a variety of procedures.

However, before the UC San Diego Extension clinical trials program was developed more than a decade ago, exposure to this knowledge was difficult to acquire and was frequently obtained only through on-the-job experience over a number of years. During the past ten years more than one-thousand professionals -- from such local and national companies as Amilyn, Pfizer, Novartis, Gen-Probe, Biogen Idec, Neurocrine, and Quintiles -- have received clinical trials certificates from UC San Diego Extension.

More information on the Latin America certificate program is available at http://www.extension.ucsd.edu/estudiosclinicos or by calling Saytel Lopez at 858-964-1058.

This news release and any accompanying images can be accessed on the web at: http://ucsdnews.ucsd.edu/newsrel/general/10-29ForClinical.asp

Learn more about UC San Diego. Subscribe to ThisWeek@UCSD: http://email.e-mailnetworks.com/phase2/survey1/survey.htm?cid=fgnvtx

UCSD News on the web at: http://ucsdnews.ucsd.edu Media Contact: Henry DeVries (858) 534-9955 or hdevries@ucsd.edu
'/>"/>

SOURCE University of California San Diego Extension
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. San Diegos Original Biotech Company Celebrates 30th Anniversary With Reunion
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
4. DermTech and Rady Childrens Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
5. Gable PR Honored by PRSA San Diego Chapter with Three Awards for Client Programs
6. Genetic clock makers at UC San Diego publish their timepiece in Nature
7. San Diego universities, government and industry rally around local Clean-Tech cluster
8. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
9. A Scientific Milestone: Sex of Dolphin at SeaWorld San Diego Determined Prior to Conception
10. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
11. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... 1, 2017  Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... to the life sciences industry, today announced the launch ... reproductive health market. CryoStork SM Next Flight Out ... for reproductive health patients, providing express transportation across ... for reproductive health commodities such as sperm, eggs, embryos ...
(Date:3/1/2017)... SHANGHAI , March 1, 2017 ... Cork based Biotechnology Company and HD ... discovery Contract Research Organization (CRO), announced today that ... and provide new assay technologies for preclinical drug ... access to Luxcel,s state-of-the-art assays and technologies for ...
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... ... , ... Surface Plasmon Resonance (SPR) is a widely-used, label-free technique to characterize ... changes in the dielectric properties of the medium close to a metal surface. ... to 300 nm above the metal surface (Au) and thus by the material absorbed ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):